Autologous stem cell therapy (Shire)

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameAutologous stem cell therapy (Shire)

Drug Alias NameAdult stem cell therapy for chronic myocardial ischaemiaCD34+ autologous stem cell therapyCD34+ cell therapy (Shire)

ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Adult stem cell therapyCell and gene therapy > Cell therapy > Donor > Autologous

Mechanisms of ActionCell replacementsAngiogenesis inducersHematopoietic progenitor cell antigen CD34 modulators

TargetsHematopoietic progenitor cell antigen CD34

Therapy Area/IndicationsCoronary DiseaseAngina PectorisMyocardial Ischemia

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Phase 3 Clinical)

Highest Status in ChinaN/A

Originator CompaniesShire Development Llc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesLisata Therapeutics Inc

Active IndicationsN/A

Inactive IndicationsCoronary DiseaseAngina PectorisMyocardial Ischemia

Other Information

ATC CodeN/A